Depression
03/07/2024
The COMP005 study is looking into a new investigational treatment approach for people with treatment-resistant depression (TRD). TRD is depression that has failed to respond to treatment with 2, 3 or 4 pharmacological medications.
- You may be able to join this study if you:
- Are 18 years of age or older
- Have major depression and have not responded to antidepressant
The study, which will last up to 62 weeks, will compare the effectiveness of an investigational medicine versus placebo, a substance that has no therapeutic effect, given with psychological support. If you are interested in learning more about the COMP005 study, you can find out more by visiting www.compasspathfinderstudies.com.
You can also call us at your local study center to find out more.
Please note that expressing an interest does not oblige you in any way to take part in the study. So please, do get in touch if you want to find out more. Reimbursement may be available for time and travel.
Contact: Nikolas Martinez @ 774-455-4143
IRB ID STUDY00000671-AJRothschild
________________________________________________________________________
54135419TRD4005 Study RECRUITMENT CLOSED
We are currently enrolling participants with treatment-resistant depression (TRD) in a clinical research study to look at the effectiveness, safety, and usefulness of an investigational nasal spray medication when it is used alone to improve depressive symptoms.
Participants must:
•be 18 years of age or older
•have been diagnosed with treatment-resistant depression
•have not adequately responded to at least 2 different antidepressant treatments
•must be comfortable with using a nasal spray
•not be pregnant or have plans to become pregnant
Subjects will be randomly assigned to receive study drug or placebo, and receive some study-related care at no cost. Study participation will last up to 24 weeks. Compensation for expenses and travel will be provided for qualified participants.
Contact Nikolas Martinez @ 774-455-4143
IRB ID #: 8298-AJRothschild